Dr. Carrye Cost, MD
Claim this profileChildren's Hospital Colorado
Area of expertise
Osteosarcoma
Carrye Cost, MD has run 5 trials for Osteosarcoma. Some of their research focus areas include:
Soft Tissue Sarcoma
Carrye Cost, MD has run 3 trials for Soft Tissue Sarcoma. Some of their research focus areas include:
Affiliated Hospitals
Children's Hospital Colorado
Children's Hospital Of Colorado
Clinical Trials Carrye Cost, MD is currently running
Losartan + Sunitinib
for Osteosarcoma
This trial is testing a combination of two drugs, Losartan and Sunitinib. It aims to find the highest dose that patients can handle without severe side effects. The study will first increase doses to find the limit, then test how well that dose works. Sunitinib has been studied extensively with other drugs for advanced solid tumors, showing varying degrees of success and side effects.
Recruiting
1 award
Phase 1
39 criteria
Onivyde + Talazoparib/Temozolomide
for Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm. In Arm A, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and talazoparib. Onivyde works by damaging the DNA of the cancer cell and talazoparib works by blocking the repair of the DNA once the cancer cell is damaged. By damaging the tumor DNA and blocking the repair, the cancer cells may die. In Arm B, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and temozolomide. Both of these medications work by damaging the DNA of the cancer call which may cause the tumor(s) to die. Once the highest doses are reached in Arm A and Arm B, then "expansion Arms" will open. An expansion arm treats more children and AYAs with recurrent or refractory solid tumors at the highest doses achieved in the phase I study. The goal of the expansion arms is to see if the tumors go away in children and AYAs with recurrent or refractory solid tumors. There will be 3 "expansion Arms". In Arm A1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and talazoparib. In Arm A2, children and AYAs with recurrent or refractory solid tumors, whose tumors have a problem with repairing DNA (identified by their doctor), will receive Onivyde and talazoparib. In Arm B1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and temozolomide. Once the highest doses of medications used in Arm A and Arm B are determined, then a phase II study will open for children or young adults with Ewing sarcoma that has recurred or is refractory following treatment received after the initial diagnosis. The trial will test the same 2 combinations of therapy in Arm A and Arm B. In the phase II, a participant with Ewing sarcoma will be randomly assigned to receive the treatment given on either Arm A or Arm B.
Recruiting
1 award
Phase 1 & 2
14 criteria
More about Carrye Cost, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Carrye Cost, MD has experience with
- Gemcitabine
- Nab-paclitaxel
- Cisplatin
- Doxorubicin, Fluorouracil, Vincristine Sulfate, Etoposide, Irinotecan, Sorafenib, Gemcitabine, Oxaliplatin, Carboplatin
- Resection
- Onivyde
Breakdown of trials Carrye Cost, MD has run
Osteosarcoma
Soft Tissue Sarcoma
Hepatoblastoma
Bone Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carrye Cost, MD specialize in?
Carrye Cost, MD focuses on Osteosarcoma and Soft Tissue Sarcoma. In particular, much of their work with Osteosarcoma has involved Stage IV patients, or patients who are EWSR1-FLI1 translocation positive.
Is Carrye Cost, MD currently recruiting for clinical trials?
Yes, Carrye Cost, MD is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Carrye Cost, MD has studied deeply?
Yes, Carrye Cost, MD has studied treatments such as Gemcitabine, Nab-paclitaxel, Cisplatin.
What is the best way to schedule an appointment with Carrye Cost, MD?
Apply for one of the trials that Carrye Cost, MD is conducting.
What is the office address of Carrye Cost, MD?
The office of Carrye Cost, MD is located at: Children's Hospital Colorado, Aurora, Colorado 80045 United States. This is the address for their practice at the Children's Hospital Colorado.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.